{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:48:19Z","timestamp":1782906499901,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.7759\/cureus.111872","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:06:36Z","timestamp":1782903996000},"source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence of Fixed-Dose Dapagliflozin-Pioglitazone in Healthy Indian Adults: Results From the Randomized Crossover PRO-4 Study"],"prefix":"10.7759","author":[{"given":"J. Hari","family":"Prasath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Kurapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhamoni","family":"Baro Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamburaj","family":"Anthuvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Gadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar  S","family":"B.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study","volume":"46","author":"Cho YK","year":"2024","unstructured":"Cho YK, Kim KS, Lee BW, et al.. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study. Clin Ther. 2024, 46:662-9. 10.1016\/j.clinthera.2024.06.023","journal-title":"Clin Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S423322","article-title":"Impact of fixed combination of metformin and pioglitazone on insulin resistance of patients with type 2 diabetes: results of a randomized open-label study","volume":"16","author":"Sun R","year":"2023","unstructured":"Sun R, Yuan L, Shen Y, Shen Z, Ding B, Ma J. Impact of fixed combination of metformin and pioglitazone on insulin resistance of patients with type 2 diabetes: results of a randomized open-label study. Diabetes Metab Syndr Obes. 2023, 16:2911-9. 10.2147\/DMSO.S423322","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2024.100167","article-title":"Dapagliflozin: a new hope for the therapeutic treatment of type 2 diabetes mellitus","volume":"11","author":"Maksud N","year":"2024","unstructured":"Maksud N, Bera S, Naim MJ, et al.. Dapagliflozin: a new hope for the therapeutic treatment of type 2 diabetes mellitus. Eur J Med Chem Rep. 2024, 11:100167. 10.1016\/j.ejmcr.2024.100167","journal-title":"Eur J Med Chem Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1586\/erc.10.98","article-title":"Pioglitazone: beyond glucose control","volume":"8","author":"de Pablos-Velasco P","year":"2010","unstructured":"de Pablos-Velasco P. Pioglitazone: beyond glucose control. Expert Rev Cardiovasc Ther. 2010, 8:1057-67. 10.1586\/erc.10.98","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9378-x","article-title":"Challenges and opportunities in achieving bioequivalence for fixed-dose combination products","volume":"14","author":"Mitra A","year":"2012","unstructured":"Mitra A, Wu Y. Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J. 2012, 14:646-55. 10.1208\/s12248-012-9378-x","journal-title":"AAPS J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_129_21","article-title":"Bioequivalence study of two different dapagliflozin tablet formulations in healthy adult Indian volunteers","volume":"13","author":"Kalra S","year":"2022","unstructured":"Kalra S, Bhattacharya S. Bioequivalence study of two different dapagliflozin tablet formulations in healthy adult Indian volunteers. J Diabetol. 2022, 13:235-41. 10.4103\/jod.jod_129_21","journal-title":"J Diabetol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-026-02086-3","article-title":"Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: results from the randomized phase 3 PRO-1 trial","author":"Singh AK","year":"2026","unstructured":"Singh AK, Seshadri KG, Unnikrishnan AG, et al.. Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: results from the randomized phase 3 PRO-1 trial. Diabetol Metab Syndr. 2026, 10.1186\/s13098-026-02086-3","journal-title":"Diabetol Metab Syndr"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1055\/s-2000-8525","article-title":"Clinical pharmacokinetics of pioglitazone","volume":"108","author":"Eckland DA","year":"2000","unstructured":"Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Experiment Clin Endocrinol Diabet. 2000, 108:234-42.","journal-title":"Experiment Clin Endocrinol Diabet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4907-647","article-title":"Dapagliflozin","volume":"49","author":"Cada DJ","year":"2014","unstructured":"Cada DJ, Levien TL, Baker DE. Dapagliflozin. Hosp Pharm. 2014, 49:647-62. 10.1310\/hpj4907-647","journal-title":"Hosp Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon S","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019, 79:1135-46. 10.1007\/s40265-019-01148-3","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666010-00005","article-title":"Pioglitazone: a review of its use in type 2 diabetes mellitus","volume":"66","author":"Waugh J","year":"2006","unstructured":"Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006, 66:85-109. 10.2165\/00003495-200666010-00005","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70061","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Khan U","year":"2025","unstructured":"Khan U, Majeed Z, Khan MH, et al.. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a systematic review and meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2025, 8:e70061. 10.1002\/edm2.70061","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0696","article-title":"Efficacy and safety of high-dose pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial","volume":"50","author":"Hong JH","year":"2026","unstructured":"Hong JH, Han KA, Hwang YC, et al.. Efficacy and safety of high-dose pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial. Diabetes Metab J. 2026, 50:320-30. 10.4093\/dmj.2024.0696","journal-title":"Diabetes Metab J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0314","article-title":"Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial","volume":"48","author":"Heo JH","year":"2024","unstructured":"Heo JH, Han KA, Hong JH, et al.. Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial. Diabetes Metab J. 2024, 48:937-48. 10.4093\/dmj.2023.0314","journal-title":"Diabetes Metab J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15576","article-title":"Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: a systematic review, meta-analysis, and real-world study from an international federated database","volume":"26","author":"Anson M","year":"2024","unstructured":"Anson M, Henney AE, Zhao SS, et al.. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: a systematic review, meta-analysis, and real-world study from an international federated database. Diabetes Obes Metab. 2024, 26:2606-23. 10.1111\/dom.15576","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110685","article-title":"Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: real-world evidence from a nationwide cohort database","volume":"200","author":"Lo SC","year":"2023","unstructured":"Lo SC, Kornelius E, Liao PL, Huang JY, Yang YS, Huang CN. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract. 2023, 200:110685. 10.1016\/j.diabres.2023.110685","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484368-bioequivalence-of-fixed-dose-dapagliflozin-pioglitazone-in-healthy-indian-adults-results-from-the-randomized-crossover-pro-4-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:06:37Z","timestamp":1782903997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484368-bioequivalence-of-fixed-dose-dapagliflozin-pioglitazone-in-healthy-indian-adults-results-from-the-randomized-crossover-pro-4-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.111872","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}